The strongest line here is mental, not physical: women planning a pregnancy routinely spend months in low-grade panic about a "mutation" that around four in ten of their neighbours also carry. The science isn't subtle — five medical specialty groups plus three large heart-disease trials all land on don't bother. Skipping the test costs nothing and saves you the slow drip of methylfolate, methyl-B12, betaine, and SAMe that almost always follows a positive result.
MTHFR is a gene that codes for one enzyme in your folate cycle. The enzyme's job is to convert one form of folate into the form your cells use to make methionine — a building block in countless cellular reactions. The two common variants the test looks for, called C677T and A1298C, do mildly reduce how fast that enzyme works in a test tube. People who carry two copies of the slower version see the enzyme run at roughly 30% of normal speed in lab assays Frosst 1995.
Two things flow from that. First, this is not a rare condition. About one in three Americans of European descent carries one slow copy; one in ten carries two. In Hispanic populations the carrier rate is even higher Wilcken 2003. Calling something a "mutation" when 40% of your friends have it is a marketing word, not a medical one.
Second, the test-tube number doesn't carry over to real life. Your body has spare capacity in the folate pathway, and as long as you're eating normally — cereal, bread, leafy greens, the usual diet of a person living in a country that fortifies grain — that spare capacity covers the gap. Population data from after the US started adding folic acid to flour in 1998 confirms it: blood markers in the slow-enzyme group dropped back into the normal range Crider 2018.
The other thing worth knowing is that the popular online claim — "if you have MTHFR you can't process folic acid" — gets the biochemistry backwards. Folic acid is broken down by a different enzyme entirely, one MTHFR has no part in. MTHFR acts further down the pathway, on a different molecule. Carriers process folic acid normally Stover 2011.
What the evidence actually says
Three medical questions get used to justify MTHFR testing. The trial evidence answers all three the same way.
Does my MTHFR result tell me anything about heart disease? No. Three large trials gave at-risk patients enough B-vitamins to drop their homocysteine — the marker that MTHFR variants nudge upward — by about a quarter. Heart attacks and strokes did not budge in any of them Lonn 2006, Toole 2004, Bonaa 2006. A Cochrane review pooling every relevant trial reached the same conclusion Martí-Carvajal 2017. Lowering the number didn't reduce events; knowing your genotype changes nothing about how you'd reduce your cardiovascular risk.
Does it tell me anything about blood clots? No. The American Society of Hematology's Choosing Wisely list — its dedicated effort to flag tests doctors should stop ordering — names MTHFR explicitly: don't test for it in patients with thrombosis ASH 2013. The American College of Medical Genetics has reaffirmed the same position twice, in 2013 and again in a 2022 update Hickey 2013, ACMG 2022. Pooled studies don't find a real link between the variants and clots once homocysteine is accounted for.
Does it tell me anything about miscarriage? Also no. The OB/Gyn society's bulletin on inherited clotting risks in pregnancy lists MTHFR as not part of the workup ACOG 2018. The fertility society's recurrent-loss bulletin says the same ASRM 2012. A 2016 review in Genetic Counseling traced why doctors still occasionally order it: legacy habits from the late 1990s, not present-day evidence Levin 2016.
There's one place MTHFR genuinely connects to a real outcome: the slow-enzyme version slightly raises baseline risk for neural-tube defects in pregnancy. And here's the punchline — the protective dose of folic acid is identical for carriers and non-carriers. 400 to 800 micrograms a day, starting a month before conception MRC 1991, Botto 2000, Crider 2018. The genotype doesn't change the recommendation. Which means it doesn't justify the test.
What the marketing gets wrong
The most common claim — and the one that justifies the supplement upsell — is that carriers must take "methylated folate" instead of regular folic acid. Head-to-head pharmacokinetic studies say no. At standard doses (400 mcg, the prenatal dose), the two raise red-cell folate by essentially the same amount. Neither carriers nor non-carriers see a clinically meaningful advantage from the bioactive form Pietrzik 2010, Bailey 2015. Methylfolate costs roughly four times more than folic acid and has decades less safety data behind it for pregnancy.
The next claim is that an elevated homocysteine result, in someone who carries the variant, is itself the problem. Homocysteine looks like a disease marker — it's high in people with heart attacks, strokes, dementia, miscarriages — but the trials above show this is the wrong reading. Homocysteine is a passenger, not the driver. The studies that lowered homocysteine didn't change outcomes Martí-Carvajal 2017. Knowing your number doesn't change what to do about your heart, and the variant doesn't change what your number means.
The third claim is the "methylation pathway" framing — that one slow enzyme breaks a vast chain of reactions, and the fix is a stack of cofactors taken daily forever. This is a vivid story; it is not how the folate cycle works. The cycle has redundancy, the variants don't actually break it, and the trials of the supposed fixes don't show benefit.
What it actually does to you
The cost of saying yes to the test isn't the $99. It's what comes after a positive result, and almost every result is positive in some sense — the test is designed so that roughly half of takers find out they're a "carrier."
The week after. You read the report and Google for an hour. You join a Facebook group called something like MTHFR Moms or a subreddit with 60,000 members. The framing everywhere is identical: this is a gene mutation, you must stop taking folic acid, you need a specific stack of bioactive supplements, and the regular medical system doesn't understand.
The month after. A first order goes out: methylfolate, methyl-B12, sometimes P-5-P (the active B6), sometimes betaine. Roughly $60 to $120 the first month. You start checking ingredient labels at the supermarket because regular multivitamins contain folic acid and people in the forum say to avoid it.
The year after. The stack has grown — SAMe got added because someone mentioned mood, choline because of a fertility post, liposomal glutathione because of a podcast. You're spending around $1,500 a year on supplements that have no trial evidence behind them, and you're slightly worried whenever a meal isn't "MTHFR-friendly." Friends ask why your supplement shelf got so elaborate; the answer involves a slide deck.
If you were considering a pregnancy. The worst of the loop. A miscarriage in your past — almost everyone planning their second pregnancy has one — gets reinterpreted as the gene's fault. The next pregnancy is shadowed by it. You scroll forum threads at 2 a.m. about whether your dose of methylfolate is high enough. Your obstetrician's actual recommendation, the same 400-mcg folic acid given to non-carriers, feels insufficient because the internet says so ACOG 2018, Levin 2016. The clinical reality is that your miscarriage risk and your folic-acid prescription are no different from any other pregnant woman's — but the test result has installed a story that's hard to put down.
None of this is exotic. It's the standard arc documented in genetic counselling case series and visible in any "MTHFR" community thread. The slow-motion harm is the opportunity cost — money, attention, decision energy — spent managing a disease that the evidence says you don't have Levin 2016.
What to do instead
The genuinely useful thing to take away: your folate plan does not depend on knowing your MTHFR status. The standard advice that applies to everyone — including everyone with two slow copies of the gene — is short.
If you already paid for the test and the result is sitting in your inbox, treat the information the way you'd treat your eye colour: it's a fact about you, it's not actionable. Throw out the methylfolate; folic acid is fine.
Why this test is still everywhere
The test costs the lab a few dollars to run and sells for $99 to $400. Roughly half of buyers come back "positive." There is a thriving downstream economy — methylfolate brands, "methylation-cofactor" stacks, follow-on panels from boutique labs at $300 to $600 a round — that depends on those positives ACMG 2022. The patient is buying anxiety relief; the seller is selling a recurring revenue stream. Both sides of the transaction are doing what their incentives ask of them.
On the other side, the medical bodies that have ruled against the test (ACMG, ASH, ACOG, ASRM) don't have a marketing budget. There is no campaign telling people "the test you saw an ad for is not recommended." The default is the Google search result, the influencer post, the integrative clinic's intake form — all pointing toward yes. So it persists.
It's also still ordered occasionally by traditional doctors, often as a leftover from how thrombosis workups were done in the late 1990s. If that happens, it's fair to ask the doctor whether their plan changes based on the result. Usually it doesn't, and the order gets dropped ASH 2013.
23andMe stopped showing MTHFR in its consumer reports years ago under regulatory pressure, but the raw genotype is still downloadable, and a parallel ecosystem of third-party "interpreters" (Promethease, Genetic Genie, StrateGene) will read it for a small fee and produce the same alarming narrative FDA 2018. Avoiding the analysis is easier than disengaging from it once started.
Who gets pulled in hardest
Women in the preconception window are the highest-marketed-to audience for MTHFR testing and the highest-anxiety subgroup once a result is in hand. The combination of a first-time pregnancy, the unfamiliar weight of every choice, and an algorithm-fed feed of fertility content makes the test a near-perfect emotional product. The clinical reality to anchor on: the obstetric recommendation for a 677TT homozygote is the same recommendation given to a non-carrier — 400 to 800 mcg folic acid, periconceptional, in a standard prenatal vitamin ACOG 2018, Crider 2018. The fertility society and the OB/Gyn society both explicitly leave MTHFR out of the recurrent-pregnancy-loss workup ASRM 2012. If you've already done the test and the variant came back, your prescription does not change. If you haven't, there is nothing to gain from doing it.
The other cluster is young adults with diffuse, hard-to-pin-down symptoms — fatigue, brain fog, low mood, anxiety — who have done a 23andMe and ended up on a third-party report. The pattern from genetic counselling is consistent: the MTHFR result feels like an explanation for symptoms that have other causes, the supplement protocol provides something concrete to do, and the framework persists because it gives the person a sense of agency over a problem the regular medical system was not solving Levin 2016. The trap is real and worth naming. Symptoms in this category — when they're persistent enough to matter — generally have ordinary medical answers (sleep, iron, thyroid, depression, undiagnosed sleep apnea), not genetic ones.
Adjacent things worth knowing about
A few related topics worth a separate look:
- Periconceptional folic acid as a population health win — universal supplementation drops neural-tube defects by around 70%, no genotype testing required.
- Real thrombophilia testing — Factor V Leiden, prothrombin 20210, antiphospholipid antibodies, protein C/S, antithrombin — when someone has had an unprovoked clot or strong family history.
- B12 screening in vegetarians, vegans, and older adults, where a real deficiency is genuinely common and easy to miss.
- Direct-to-consumer genetic testing in general — what kinds of results from these panels are clinically actionable (a short list) and which ones aren't (a long list).
- Severe MTHFR deficiency, the rare inborn metabolic disease that presents in infancy with developmental and clotting problems. Confusingly shares a name with this entry's topic; it is a different thing entirely and not what any wellness clinic is testing for.
- — A positive MTHFR result almost always kicks off a methylfolate habit the evidence doesn't support — folate is the supplement actually worth knowing about.
- — MTHFR is the textbook case of a genetic test that sounds important and isn't — useful context for what genetic testing can and can't tell you.
- — Same trap, different aisle — a marketed test most every medical society says to skip, sold as personalized insight.
- — Unlike the validated drug-gene matches, an MTHFR result almost never changes treatment — a useful contrast to keep straight.
- — The supplement cascade a positive result triggers usually includes methyl-B12 too — worth knowing what B12 actually does before you start.
Substance and claimed effects
The substance covered by this entry is routine genotyping of the MTHFR gene — almost always the two common polymorphisms C677T (rs1801133) and A1298C (rs1801131) — when ordered, sold, or marketed as a tool to guide personal health decisions. The test is offered through three overlapping channels: (1) direct-to-consumer panels (23andMe raw data, Ancestry-data uploads to third-party interpreters, naturopathic mail-in kits), (2) integrative-medicine and functional-medicine clinicians who run it as part of a "methylation workup," and (3) traditional ordering by obstetricians and hematologists in the workup of thrombosis and recurrent pregnancy loss — a practice now explicitly discouraged by the relevant professional bodies Hickey 2013, ACMG 2022, ASH Choosing Wisely 2013, ACOG 2018.
Claimed downstream uses include: (i) switching all folic-acid supplements to L-5-methyltetrahydrofolate ("methylfolate") on the grounds that variant carriers cannot "methylate folate"; (ii) explaining a wide list of symptoms (fatigue, brain fog, anxiety, depression, miscarriage) by reference to a personal "MTHFR mutation"; (iii) layering on methyl-B12, B6, betaine/TMG, choline, and SAMe supplements as part of "methylation support"; (iv) assessing thrombophilia and recurrent pregnancy loss risk; (v) guiding folic-acid avoidance in food fortification. The entry covers all of these claims and the cascade of consequences (folate-form supplementation choices, family-planning anxiety, ongoing supplement spend, the boundary between evidence-based clinical genetics and DTC wellness genetics).
Evidence by addressing question
mechanism
MTHFR encodes methylenetetrahydrofolate reductase, which converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (5-MTHF), the methyl-donor form of folate used by methionine synthase to remethylate homocysteine to methionine Frosst 1995, Stover 2011. The two common variants do reduce enzymatic activity in vitro: 677TT homozygotes show roughly 70% reduced activity in lymphocyte assays at low folate; 677CT heterozygotes around 35%. A1298C has a milder effect and a less consistent phenotype Frosst 1995, Bailey 2015.
The crucial mechanistic point that the DTC narrative skips: reduced enzyme activity in an assay does not equal a clinically meaningful methylation deficit at the population level when folate intake is adequate. In folate-replete individuals, the alternate-substrate pool and dietary 5-MTHF are sufficient to keep cellular methylation cycling within normal range. Homocysteine elevation in 677TT homozygotes is modest (~25% higher than CC) and almost entirely abolished by routine folic-acid intake at the 400 mcg level Klerk 2002, Crider 2018, Moll 2015. After fortification of U.S. cereal-grain products in 1998, the median homocysteine in 677TT carriers dropped into the normal range population-wide Crider 2018.
The "you can't process folic acid" claim circulated in DTC wellness blogs reverses the actual biochemistry. Folic acid is reduced by dihydrofolate reductase (DHFR) — not by MTHFR — to tetrahydrofolate, which then enters the folate cycle. MTHFR sits downstream and acts on a different substrate. C677T carriers reduce folic acid normally; what they have is mildly impaired conversion of 5,10-methylene-THF to 5-MTHF further down the pathway, and this is bypassed by even modest dietary intake Stover 2011, Pietrzik 2010.
evidence
Three separate clinical-utility questions have to be kept apart, because the literature answers all three the same way (no benefit from testing) for different reasons.
Cardiovascular disease. Mendelian-randomization meta-analyses of MTHFR 677TT versus CC find a small effect on coronary risk in regions without folate fortification and essentially no effect where folate intake is adequate Klerk 2002, Lewis 2005. The three large homocysteine-lowering RCTs — HOPE-2 (n=5,522), VISP (n=3,680), NORVIT (n=3,749) — failed to reduce cardiovascular events despite lowering homocysteine by ~25% Lonn 2006, Toole 2004, Bonaa 2006. The 2017 Cochrane review of homocysteine-lowering interventions confirmed no effect on CV mortality, MI, or stroke Martí-Carvajal 2017. Knowing a patient's MTHFR genotype does not change cardiovascular management.
Thrombophilia. ASH Choosing Wisely explicitly tells clinicians not to order MTHFR genotyping in the thrombosis workup; ACMG concurs ASH 2013, Hickey 2013, ACMG 2022. The basis: pooled analyses show no association between MTHFR variants and venous thromboembolism once homocysteine is controlled, and even patients with biochemically meaningful hyperhomocysteinemia do not benefit from B-vitamin therapy for VTE prevention Moll 2015.
Recurrent pregnancy loss. ACOG Practice Bulletin 197 and the ASRM Practice Committee both list MTHFR (and homocysteine) testing as not indicated in the standard workup of recurrent pregnancy loss ACOG 2018, ASRM 2012. The 2016 Journal of Genetic Counseling review traced the persistence of the test in practice to legacy ordering patterns from the late 1990s rather than current evidence Levin 2016. A small pro-testing literature persists in the assisted-reproduction subspecialty (e.g., Servy 2018) but rests on uncontrolled case series and supplement-trial-of-one designs.
Neural-tube defect prevention. The single area where MTHFR has any historical connection to a real clinical outcome — and even here the recommendation is universal supplementation, not genotype-stratified care. Periconceptional folic acid prevents ~70% of neural-tube defects in the general population MRC 1991, Wald 2001. MTHFR 677TT carriers have a modestly elevated baseline risk; the same dose of folic acid is protective Botto 2000, Crider 2018. Public-health bodies recommend 400 mcg folic acid for all women planning pregnancy regardless of genotype.
misconceptions
The dominant DTC misconception is that "I have an MTHFR mutation" describes a rare, personal medical condition. The C677T T allele has carrier frequencies of 25–50% across most studied populations (Hispanic ~50%, European ~35–45%, East Asian ~30%, African ~10%) Wilcken 2003. Between one-third and one-half of every reader is heterozygous; ~10–12% of Europeans are homozygous. A "mutation" with double-digit population prevalence is not a mutation in any informative clinical sense; it is a common polymorphism.
Second: that folic acid is harmful to "MTHFR mutants" and methylfolate is mandatory. Head-to-head pharmacokinetic comparisons of L-5-MTHF and folic acid show essentially equivalent rises in red-cell folate at equivalent doses, with no advantage of methylfolate for either C677T carriers or non-carriers at standard 400 mcg doses Pietrzik 2010, Bailey 2015. The "unmetabolized folic acid in serum" finding — sometimes cited as evidence of harm — is a marker of high-dose intake, not a demonstrated clinical risk.
Third: that elevated homocysteine, when present in an MTHFR carrier, is itself the disease. Homocysteine is a biomarker, not a causal lever — the failure of homocysteine-lowering trials to alter cardiovascular endpoints establishes this Martí-Carvajal 2017.
practicalities
Routine MTHFR genotyping in the U.S. retails between $99 (online add-on) and $300–400 (clinic-ordered panel). It is not covered by insurance for any non-thrombophilia indication; ACMG's stance makes it harder to bill clinically ACMG 2022. The larger ongoing cost is the supplement cascade that typically follows a positive result: L-5-MTHF ($25–45/month), methyl-B12 ($15–30/month), B6 P-5-P ($15/month), TMG/betaine ($15–25/month), and frequently SAMe ($40–80/month) — a routine $1,000–2,500 annual spend. Boutique "methylation panels" (Doctor's Data, Genova Diagnostics) layer further: $300–600 per round, often repeated. None of this spend has clinical-trial evidence behind it.
Once a person carries the genotype label, removal from product labels is non-trivial: many multivitamins, prenatals, and even fortified breads contain folic acid by default, prompting continual ingredient checking.
stakes
The reader who acts on a positive MTHFR result enters a stable, self-reinforcing pattern. The supplement stack grows over time as new "methylation cofactors" appear in DTC marketing. Family-planning anxiety is the load-bearing emotional driver: women considering pregnancy who learn they are 677TT often spend months researching whether their genotype contributed to past miscarriage or will threaten future ones — when the actual obstetric recommendation is identical to that for non-carriers (400 mcg folic acid, periconceptional) Crider 2018, ACOG 2018. The opportunity cost of this attention — money, decision energy, anxiety bandwidth — is real even though the disease risk being managed is not.
protocol
The evidence-based protocol for a member of the general population is identical regardless of MTHFR status:
- For women planning pregnancy: 400–800 mcg folic acid daily starting at least one month before conception, continuing through the first trimester MRC 1991, ACOG 2018.
- For the general adult: a normal diet supplying folate via leafy greens, legumes, and fortified grains is adequate. No targeted supplementation is required absent a deficiency.
- For elevated homocysteine (when measured for an independent indication and clinically significant — generally >15 µmol/L): treat with conventional B-vitamin replacement, but understand that lowering the number has not been shown to reduce events Martí-Carvajal 2017.
- For confirmed VTE or recurrent pregnancy loss: pursue the standard hematology / MFM workup — antiphospholipid antibodies, Factor V Leiden, prothrombin 20210, protein C/S, antithrombin — and skip MTHFR ASH 2013, ACOG 2018.
audience
Preconception and pregnant women are the highest-anxiety subgroup and the highest-marketed-to. The integrative-fertility ecosystem (IVF add-ons, "preconception coaches," fertility-supplement brands) leans heavily on MTHFR. Young adults with diffuse symptoms (fatigue, anxiety, brain fog) who have done a DTC test are the second cluster. Older adults are less commonly drawn in because the marketing framing emphasises "lifelong methylation support" from a young age.
contraindications
Not applicable — the action is avoidance of a test, not consumption of a substance. The one genuine adjacent risk worth noting: very high-dose folic acid (>1 mg/day) in older adults with low B12 can mask the hematologic signs of B12 deficiency while allowing neurologic deterioration to continue. This is an argument against megadose supplementation, not against fortification.
out-of-scope
Adjacent and useful: real thrombophilia workup (Factor V Leiden, prothrombin 20210, antiphospholipid), homocysteine measurement when an independent indication exists, B12 screening in vegetarians and older adults, periconceptional folic acid as a population intervention. Out of scope: the small subset of patients with the genuine inborn error of metabolism severe MTHFR deficiency (rare, presents in infancy with developmental and thrombotic disease) — a distinct entity from C677T/A1298C polymorphism.
The credibility range
Optimist case
The strongest pro-testing position: (i) MTHFR variants are real and do reduce enzyme activity in vitro; (ii) some studies of recurrent pregnancy loss and hyperhomocysteinemia find associations in folate-deplete subgroups; (iii) for the small population of 677TT homozygotes with measured low red-cell folate and high homocysteine, supplementing with the bioactive 5-MTHF form may give faster correction than folic acid at very high doses Pietrzik 2010, Servy 2018; (iv) personal information has value beyond clinical-utility-trial endpoints — some readers act on a known variant by tightening their diet in ways that incidentally improve health. A defender would argue ACMG's "no clinical utility" call addresses the formal billable-test question, not whether self-knowledge has any value.
Skeptic case
The skeptic case is the dominant one in the literature and at every relevant guidelines body. (i) The variants are too common to count as "mutations" in a useful clinical sense — labelling 40% of the population with a disease-flavoured term is a category error Wilcken 2003, Levin 2016. (ii) The mechanism is bypassed at ordinary folate intake; the effect is measurable in assays and irrelevant in life Crider 2018. (iii) The downstream therapeutic claims (methylfolate over folic acid, B-vitamin stacks for "methylation support") have failed in every adequately powered trial that has tested them Lonn 2006, Toole 2004, Bonaa 2006, Martí-Carvajal 2017. (iv) The commercial incentive structure is unusually concentrated — DTC labs, supplement manufacturers, and a small subspecialty of integrative practitioners all benefit financially from a positive result, and there is no countervailing force pushing patients off the pathway once they enter. (v) The Levin 2016 review documents real harm: patients delaying evidence-based workup, choosing methylfolate over standard folic acid in pregnancy on incorrect grounds, and accumulating supplement spend with no benefit Levin 2016.
Author's call
The skeptic case carries this entry. Every major specialty society that has examined the question — ACMG twice (2013, 2022), ASH via Choosing Wisely, ACOG, ASRM — concluded that routine MTHFR genotyping has no clinical utility outside research and the rare severe deficiency. The cardiovascular RCT evidence against the mechanism is as strong as RCT evidence against a marketed intervention ever gets. The remaining honest uncertainty is at the margins (assisted-reproduction subspecialists who order it, individual cases of measurably elevated homocysteine where 5-MTHF may correct faster than folic acid). For the catalogue's reader — a person considering a DTC panel or being offered MTHFR testing in a wellness clinic — the answer is don't, and if you already have the result, ignore it and take 400 mcg folic acid like everyone else.
Stakeholder and incentive map
- DTC genomics companies (23andMe historically; raw-data third-party interpreters like Promethease, Genetic Genie, StrateGene): MTHFR is a high-attention "result" that drives engagement; until 2017 it appeared prominently in 23andMe consumer reports. Even after companies removed it from their primary panels under FDA pressure, the raw genotype remains accessible and the third-party ecosystem persists FDA 2018.
- Supplement manufacturers (Thorne, Seeking Health, Pure Encapsulations, Designs for Health, Quatrefolic and Metafolin brand-licensees): direct economic beneficiary of methylfolate / methylated-B-complex sales tied to a positive MTHFR result. Pricing is several times that of folic acid.
- Functional / integrative medicine practitioners: MTHFR panels and "methylation analysis" are core revenue lines and central to the field's identity. Notable advocates (Ben Lynch, Amy Yasko) built businesses around MTHFR interpretation.
- Patient communities: large Facebook groups, subreddits, and forums where "MTHFR moms" share supplement protocols. The community provides emotional support and persistent reinforcement of the framework, including resistance to mainstream medical advice.
- Counter-incentives: ACMG, ASH, ACOG, ASRM, NIH genetics arms, mainstream OB/Gyn, hematology. Less commercial reach than the testing-positive side. Choosing Wisely is the most active de-implementation effort ASH 2013.
- IVF / assisted-reproduction clinics: mixed. Some include MTHFR in standard panels (legacy ordering; revenue from add-ons); larger academic centers follow ASRM and exclude it.
Population variability
- Allele frequency by ancestry. 677T frequency is highest in Hispanic / Latino populations (~45–50%), moderate in European-descent (~30–40%), lower in East Asian (~25–35%) and African-ancestry (~10%) populations Wilcken 2003. Homozygote frequency tracks accordingly.
- Folate status modifies everything. The phenotype of 677TT depends on dietary and supplemental folate. In a folate-replete person, the variant has minimal functional consequence; in a deplete person (rare in fortified countries; possible in adolescents, eating-disorder histories, severely restricted diets), the variant matters more.
- Severe homozygous deficiency (compound heterozygous null alleles, not the common variants) is a distinct rare disease — homocystinuria-like, presents in infancy. Out of scope here.
- Older adults have the masked-B12-deficiency concern at high folic-acid doses — argues for diet-level supply, not megadosing, regardless of MTHFR status.
Knowledge gaps
What would change the call: a large RCT randomising MTHFR 677TT carriers to L-5-MTHF versus folic acid at equivalent doses, with hard endpoints (live birth rate, recurrent miscarriage, NTD, MI). None exists; none is plausibly worth running given the consistent null on the relevant biology. A more interesting open question: whether unmetabolised folic acid at the population level — a real biochemical observation in fortified countries — has long-term consequences. Current evidence is reassuring but the longest follow-up cohorts are only ~25 years old. This is a question about fortification policy, not about individual MTHFR testing, and does not change the entry's recommendation.
Also genuinely open: whether the broader category of "consumer methylation testing" (which extends beyond MTHFR to MTRR, MTR, COMT, BHMT, etc.) has any individual-level signal worth extracting. The consensus answer remains no, but the panels are newer than the MTHFR-only literature.
Scope. The brief asked for routine MTHFR genotyping marketed for health and methylation decisions, its standing per major guidelines, and four downstream consequences (folate-form choices, family-planning anxiety, supplement spend, the DTC-vs-evidence-based boundary). The article covers all four end-to-end. No silent narrowing.
Hard scoping call: severe MTHFR deficiency. The rare inborn error of metabolism with the same name (compound heterozygous null alleles, infantile presentation) is genuinely a different condition and is not what anyone discussing the common polymorphism is talking about. Mentioned briefly in the article's out-of-scope section to head off the name-collision confusion; not given its own treatment. Future entry candidate if the catalogue grows into rare-disease territory.
Hard scoping call: homocysteine testing. Closely adjacent and arguably part of the same wellness package, but a distinct test with a distinct (modestly better) clinical case for it in cardiovascular and B12-deficiency contexts. Pointed to in out-of-scope; deserves its own entry. The related field references homocysteine-testing for future wire-up.
Rating difficulty: action verb and cadence. Considered know + once (literacy framing) versus avoid + once (decision framing). Landed on avoid because the entry's payload is a recommendation, not just information — the active call is "don't order this test, don't act on the result if you already have one." Cadence once because the decision-not-to-test is a one-time call, and the literacy is one-and-done.
Rating difficulty: mood at 2 vs 1. For the typical catalogue reader who hasn't heard of MTHFR, avoiding the test has no mood effect. For the subset that would have been pulled into the testing-and-supplement spiral (preconception women, anxious DTC-test takers), the mood effect is substantial. Settled on 2 as a weighted call across the audience the entry actually reaches, with the qualifier in the justification. Defensible to argue 1.
Rating difficulty: controversy at 3. Mainstream science is settled (would suggest 1–2); a loud, well-funded counter-position in functional medicine and the DTC supplement industry keeps the topic in active dispute in the marketplace if not in the literature (would suggest 3–4). Landed on 3 — a genuine guideline-vs-marketplace split rather than an open scientific question.
Excluded. Other "methylation panel" variants (MTRR, MTR, COMT, BHMT) — same critique applies but the literature is thinner and the test is much less common as a standalone product; mentioned briefly in research §6 knowledge gaps. Not given separate article treatment.
Excluded. Detailed thrombophilia workup (Factor V Leiden, prothrombin 20210, antiphospholipid, protein C/S, antithrombin) — adjacent and useful but a separate entry on its own. Forward-pointed in out-of-scope.
Future-link candidates referenced in the related field but not yet existing: folic-acid-preconception, homocysteine-testing, dtc-genetic-tests. All three would slot in cleanly when written.
Category placement. Could fit medical (a healthcare test), screening (a genetic screen), or supplements (because the cascade is supplement-driven). Picked screening because the entry's action is the screening-decision, and the supplement cascade is downstream rather than primary.
MTHFR Testing
Every major medical group that has looked at this — geneticists, blood doctors, OB/Gyns — says don't order it. Big trials back them up.
Skipping the test skips the family-planning panic — the "did my gene cause my miscarriage?" loop that has no clinical answer to give.
A small daily-life win: no methylfolate, no methyl-B12, no betaine, no SAMe sitting on the counter for no reason.